Catalyst
Slingshot members are tracking this event:
Alkermes' phase 3 study on schizophrenia treatment ALKS-3831 looking at Olanzapine Insulin Sensitivity and Lipid Metabolism in young adults to begin second quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 01, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2268180
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Insulin Sensitivity, Lipid Metabolism, Olanzapine, Alks-3831, Schizophrenia, Phase 3 Study
